All lobbying filings

MARSHALL & POPP, LLC

Lobbying for JAZZ PHARMACEUTICALS, INC. AND ITS SUBSIDIARIES, INCLUDING GREENWICH BIOSCIENCES · Pharmaceuticals.

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2025 · California · House · Senate · $40,000.00 income · posted Apr 21, 2025

Official filing document

Bills named in this filing 4

HR 1492
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…
HR 946
ORPHAN Cures Act
HCONRES 14
Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appro…
SCONRES 7
An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal ye…

Lobbying activity 2

Health Issues

Issues related to the research and development of cannabis-derived therapies and FDA's regulatory framework for CBD. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug value, including H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; H.R. 946, Orphan Cures Act; and implementation of the Inflation Reduction Act (PL 117-169). Issues related to the regulation of hemp-derived cannabinoids. H.R.946 - ORPHAN Cures Act.

Budget/Appropriations

Issues related to budget reconciliation, including H.Con.Res. 14 and S.Con.Res. 7.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.